Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive drug targets tough prostate cancer in early trial

NCT ID NCT07581184

Recruiting now Disease control Sponsor: Aktis Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen May 13, 2026 · Last updated May 13, 2026

Summary

This early-phase study tests a new radioactive drug called [225Ac]Ac-AKY-2519 in people with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The drug targets a protein (B7-H3) on cancer cells to deliver radiation directly to tumors. About 138 adults will take part to check safety, side effects, and whether the drug shrinks tumors. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BAMF Health

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Biogenix Molecular, LLC

    RECRUITING

    Miami, Florida, 33165, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B7H3 CASTRATION-RESISTANT METASTATIC PROSTATE CANCER MCRPC MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) PROSTATE CANCER